scispace - formally typeset
J

Jun Wang

Publications -  13
Citations -  1367

Jun Wang is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 7, co-authored 8 publications receiving 913 citations.

Papers
More filters
Journal ArticleDOI

Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19

TL;DR: COVID-19 severity is associated with increased IgG response, and an immune response phenotyping based on the late IgG responded and NLR could act as a simple complementary tool to discriminate between severe and non-severe COVID- 19 patients, and further predict their clinical outcome.
Journal ArticleDOI

Clinical characteristics of 82 cases of death from COVID-19.

TL;DR: Respiratory failure is the main cause of COVID-19, but the virus itself and cytokine release syndrome-mediated damage to other organs, including cardiac, renal, hepatic, and hemorrhagic damage, should be taken seriously as well.
Posted ContentDOI

Clinical characteristics of 82 death cases with COVID-19

TL;DR: Older males with comorbidities are more likely to develop severe disease, even die from SARS-CoV-2 infection, but either virus itself or cytokine release storm mediated damage to other organ including cardiac, renal, hepatic, and hemorrhage should be taken seriously as well.
Posted ContentDOI

Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19

TL;DR: COVID-19 severity is associated with increased IgG response, and an immune response phenotyping based on late IgG responded and NLR could act as a simple complementary tool to discriminate between severe and nonsevere COVID- 19 patients, and further predict their clinical outcome.
Journal ArticleDOI

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.

TL;DR: This review summarizes the current understanding and clinical development of combination therapy with immune checkpoint blockade and anti-angiogenic strategy and shows an improved anti-cancer efficacy and prolonged survival following the addition of anti-angaogenic agents to ICIs.